EP1226267A1 - Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs - Google Patents

Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs

Info

Publication number
EP1226267A1
EP1226267A1 EP00972941A EP00972941A EP1226267A1 EP 1226267 A1 EP1226267 A1 EP 1226267A1 EP 00972941 A EP00972941 A EP 00972941A EP 00972941 A EP00972941 A EP 00972941A EP 1226267 A1 EP1226267 A1 EP 1226267A1
Authority
EP
European Patent Office
Prior art keywords
product
peptides
milk
fermentation
casein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00972941A
Other languages
German (de)
English (en)
Other versions
EP1226267B1 (fr
Inventor
Olli Tossavainen
Tarja Suomalainen
Janne Sahlstein
Annika Mäyrä-Mäkinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valio Oy
Original Assignee
Valio Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valio Oy filed Critical Valio Oy
Publication of EP1226267A1 publication Critical patent/EP1226267A1/fr
Application granted granted Critical
Publication of EP1226267B1 publication Critical patent/EP1226267B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
    • A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
    • A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/147—Helveticus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the invention relates to a process for preparing a product containing antihypertensive peptides.
  • the invention also relates to the obtained prod- uct and its use as a functional product as such or as an ingredient or additive in edible substances.
  • cardiovascular diseases are counted among the most common national diseases in developed countries and their occurrence will further increase as the population grows older. High blood pressure contributes considerably to the development of these diseases. Therefore, treating hypertension is one of the most important measures regarding both prevention and effective treatment.
  • an angiotensin-l-converting enzyme In blood pressure control, an angiotensin-l-converting enzyme, ACE, has a key role on a cell level. ACE functions in two ways: it converts an- giotensin I to angiotensin II which is a strong vasopressor and inactivates bradykinin which, in turn, has a vasodilatory effect. Thus, both functions lead to elevated blood pressure. ACE inhibitors may inhibit this effect and consequently act as antihypertensive agents. Many known pharmaceuticals used in treatment of hypertension are ACE inhibitors. One of these is captopril, i.e. D- 2-methyl-3-mercaptopropanoyl-L-proline, which is commercially available in Finland under trade names Capoten (by Bristol-Myers Squibb) and Captopril Generics (by Merck Generics).
  • Fermented milk products have been reported to contain peptides having an antihypertensive effect. It is assumed that the peptides are produced in the milk products as a result of milk protein hydrolysis effected by lactic acid bacteria and particularly extracellular proteinases thereof.
  • Yamamoto et al. describe purification and characterisation of a proteinase derived from the micro-organism Lactobacillus helveti- cus CP790. Yamamoto et al.
  • the active compounds were both tripeptides, Val-Pro-Pro and lle- Pro-Pro.
  • the publication does not describe an in vivo antihypertensive effect of the tripeptides and the sour milk product prepared with the starter, but it is mentioned to be the next subject of research.
  • US Patent 5,449,661 discloses the preparation of a peptide containing the tripeptide sequence Val-Pro-Pro and its use for low- ering high blood pressure.
  • the peptide is prepared by fermenting fat-free milk powder with the Lactobacillus helveticus strain JCM-1004, whereafter the peptide is purified chromatographically and freeze-dried.
  • lactic acid is acidic and gives a bitter taste to the product containing an- tihypertensive peptides, in addition to which many consumers find the high acidity and low pH unpleasant.
  • a large number of monovalent ions, particularly sodium ions, are also present in the product containing antihypertensive peptides prepared by fermentation. These ions are known to elevate blood pressure, and hence they act in the opposite direction from the desired, antihypertensive peptides.
  • Prior art discloses methods of purifying peptides produced in fermentation. These methods allow to partly avoid the above disadvantages, while a concentrated product is obtained.
  • the object of the prior art methods has been to provide pure products that are suitable for analyses and activity tests.
  • the methods are multi-step methods that mainly consist of various chromatographic purifications and that are not suitable for large- scale production.
  • the object of the present invention is thus to provide a product having a high content of antihypertensive peptides and consequently having an antihypertensive effect.
  • the product of the invention has an advantageous salt content, which means that the amount of harmful monovalent cations is low and the amount of beneficial divalent cations is high as compared with a known product of similar type.
  • the object of the present invention is also to provide a process for preparing such a product, which process is simple and easy to carry out and therefore suitable for manufacturing the product on an industrial scale.
  • the object of the present invention is to provide the product for use as such as an antihypertensive agent or in the manufacture of edible functional foods or pharmaceuticals.
  • the object of the present invention is to provide for use orally ingested products, such as functional foods and pharmaceuticals, which contain the above-described product as one of the active ingredients.
  • a pre-preparation containing antihypertensive peptides is produced by fermentation, whereafter it is concentrated and the composition is finalized by nanofiltration.
  • the combination according to the invention provides excellent possibilities to use starting materials of different types and to modify the composition of the end product to be of the desired type, as will be described in greater detail in the following.
  • the invention relates to a process for preparing a product containing antihypertensive peptides, the process being characterized by comprising the steps of fermenting a casein-containing starting material with a lactic acid bacterium and performing nanofiltration on the obtained, peptide- containing fermentation product.
  • the invention also relates to a product containing antihypertensive peptides, which product is characterized by having a high content of antihypertensive peptides and being prepared by a process in which the casein- containing starting material is fermented with a lactic acid bacterium and the obtained peptide-containing fermentation product is nanofiltrated.
  • the invention also relates to the use of the above-described product as an antihypertensive agent.
  • the invention further relates to the use of the above-described product in the manufacture of edible substances.
  • the invention also relates to edible products containing the above- mentioned concentrated product with high peptide content and conventional ingredients of said end products.
  • a pre- preparation containing antihypertensive peptides is produced by fermentation.
  • the starting material to be used can be any product which contains sequences of desired antihypertensive peptides as a part of their own peptide or protein sequence.
  • Milk protein, particularly casein is advantageously used as such or in the form of various preparations.
  • suitable starting materials also include various casein-containing milk products, such as fat-free milk, or milk with varying fat content, as such or in the form of corresponding milk powder, and fermented milk products, such as sour milk, buttermilk, yogurt, curdled milk, unripened cheeses, etc.
  • Fermentation can be carried out with any lactic acid bacterium that is capable of producing antihypertensive tripeptides from the starting material.
  • Suitable lactic acid bacteria can be found among species of e.g. Lactobacillus, Lactococcus, Leuconostoc, Streptococcus and Bifidobactehum genera. Lacto- bacillus helveticus is the most proteolytic of the lactic acid bacteria, and therefore it is considered particularly suitable for this purpose.
  • An advantageous Lactobacillus helveticus strain is L. helveticus LBK-16H.
  • Lactic acid bacteria can be used as pure cultures or mixed cultures, separately or with conventionally used and commercially available starters. Lactic acid bacteria can also be used together with other microorganisms. As regards combinations of microbes, appropriate combinations are selected to the effect that the best possible flavour is achieved in the end product and any contamination risk is avoided.
  • Fermentation conditions are selected to meet the requirements of the strain to be used in the fermentation such that a sufficient amount of antihypertensive peptides is formed to provide a desired effect. Selection of suitable conditions, such as temperature, pH and aeration, are part of the knowhow of a person skilled in the art. The temperature can be 30 to 45 °C, for instance. Fermentation is allowed to continue until the desired amount of antihypertensive peptides is formed. Normally, this takes about 20 to 30 hours, preferably 22 to 24 hours.
  • VPP Val-Pro-Pro
  • IPP lie-Pro-Pro
  • the cell suspension is recovered. It can be used as such in a next step, i.e. for separating and concentrating peptides.
  • the cell suspension can also be concentrated, for instance, by evaporation or by drying it partly or completely, such as by spreading it onto a plate, drying and fi- nally grinding it to well presentable dry powder.
  • the fermented product may be appropriate to subject the fermented product to a pretreatment, for instance, to remove casein or all milk proteins therefrom prior to nanofiltration.
  • the methods applicable to the pretreatment are known in the field and comprise e.g. various precipitation and filtration methods.
  • One useful method comprises adjusting pH of the fermented product to a region where casein precipitates, e.g to 4.6 at a temperature of about 37 °C, whereafter the precipitated casein is separated by means of a curd separator, a casein separating sieve, a decanter or by depositing or some other suitable method.
  • a second method comprises ultrafiltration of the fermented product, at a pH of 3 to 3.5, whereby all proteins are retained on the mem- brane and the obtained permeate is nearly protein-free whey.
  • Coprecipitation which produces nearly protein-free, peptide-containing whey can be achieved, for instance, with addition of CaCI 2 , heat treatment or addition of acid.
  • possible casein dust is removed by centrifugation.
  • Other substances, such as lactose can also be removed prior to nanofiltration, for in- stance, by enzymatic hydrolysis or fermentation.
  • the fermentation product which has possibly been pretreated in an appropriate manner, such as the whey obtained as described above, is then subjected to nanofiltration.
  • a conventional NF membrane such as Nanomax- 50 (Millipore) or Desal 5 (Desal Inc., USA), can be used as the nanofiltration membrane, and the conditions are selected to meet the requirements and instructions of membrane manufacturers. Selection of the nanofiltration membrane type and process conditions contribute considerably to the composition of the resulting peptide fraction, in particular to the salt and sugar composition.
  • the nanofiltration is performed to a de- sired dry matter content or volumetric concentration ratio, which generally is as high as possible.
  • the dry matter content is in the order of about 20 to 40 % and the volumetric concentration ratio is about 5 to 20.
  • the (whey) concentrate can be diluted with water, whereby more salts and lactic acid can be removed from the concentrate in nanofiltration. This is a simple and efficient way to adjust the amount of salts in the concentrate to the desired level.
  • Small peptides such as the tripeptides IPP and VPP of about 350 D, formed in fermentation and having an effect on blood pressure, are completely retained by means of the nanofiltration membrane.
  • the process of the invention also enables complete removal of lactose: prior to the nanofiltration step, lactose can be enzymatically degraded, whereby the major part of the monosaccharides are removed.
  • lactose can be enzymatically degraded, whereby the major part of the monosaccharides are removed.
  • lactic acid, small-molecular nitrogen compounds, such as urea, and monovalent salts also permeate the membrane.
  • the peptide content of the product increases by means of the nanofiltration.
  • divalent ions in particular the desired calcium and magnesium ions
  • monovalent ions such as sodium, potassium and chloride ions
  • sodium ions are known to have a considerable effect on the fluid balance and blood pressure in the human body, and therefore a decrease in the amount of these harmful ions can be regarded as a very considerable advantage.
  • Calcium and magnesium ions are known to contribute to lowering the blood pressure, and a high content of these ions is considered very desirable.
  • Table 1 shows how the components in the pre-preparation formed in the fermentation step of the process according to the invention behave in the nanofiltration step.
  • the composition is presented by way of example to illustrate the invention and it is produced by fermenting fat-free milk with a Lactobacillus helveticus strain.
  • other products can be used as starting materials.
  • fermentation conditions, nanofiltration and other pretreatments and additional treatments, if any, contribute to the outcome, so the composition and the nanofiltration re- suits of the end products may vary and differ from those presented herein.
  • the product concentrated for antihypertensive peptides and obtained by the process of the invention can be used as such as an antihypertensive agent.
  • the product can also be dried and used in the form of a powder or a lyophilized preparation.
  • the product is advantageously used in the manufacture of functional foods or other products, however.
  • the term food is used in a broad sense covering all edible products which can be in solid, gelled or liquid form, and covering both ready-to-eat products and products to which the product of the invention is added in connection with consumption, as an additive or to be a constituent component of the product.
  • foods can be products of dairy industry, meat processing industry, food processing industry, beverage industry, baking industry and confectionery industry.
  • Typical products include milk products, such as yogurt, curdled milk, curd cheese, sour milk, buttermilk and other fermented milk beverages, unripened cheeses and ripened cheeses, snack fillings, etc.
  • Beverages, such as whey beverages, fruit beverages and beers, constitute another important group.
  • the product obtained according to the invention is used in an amount sufficient to provide the desired, antihypertensive effect.
  • the amount to be used depends significantly on the concentration degree of the whey, being e.g. 0.1 to 30 %, preferably 5 to 15 %, calculated from the weight of the end product.
  • the process of the invention and in particular its nanofiltration step, provide a good framework for preparing a product of the desired type, it is also possible to reduce the contents of components having an adverse effect on taste or to remove said components completely and consequently to preserve or even improve the taste of the product.
  • the product containing antihypertensive peptides can be added to a food during the manufacturing process or to a ready-processed food.
  • Said foods thus contain the above-described concentrated product containing antihypertensive peptides in addition to other ingredients that are conventional in such foods, and their taste and use completely correspond to those of the conventional products.
  • the two-step process according to the invention provides a product which has a considerably higher content of antihypertensive peptides than the products produced only by fermentation.
  • the process also readily allows to adjust contents of salts and their mutual proportions to a desired level.
  • it is possible to raise the content of desired divalent ions and to reduce the content of harmful monovalent ions.
  • the process is simple and inexpensive, and it is well suited for large-scale production, and in this respect it differs from the prior art processes.
  • the protein fraction obtained from the separation of casein or total protein can be used correspondingly in the manufacture of antihypertensive products, such as the above-described milk products or sausages, for instance.
  • the process is thus highly economical on the whole.
  • ACE inhibitory activity was determined for the peptides IPP and VPP and for a known ACE inhibitor, lisinopril, on the basis of the so-called inhibitor constant (Holmquist B., Bunning P., Riordan J.F., A continuous spec- trophotometric assay for angiotensin converting enzyme, Analytical Biochem- istry 95 (1979) 540-548).
  • the results were as follows: IPP 4.4 x 10 "6 , VPP 1.8 x 10 "5 and lisinopril 7.5 x 10 "9 . IPP and VPP were thus found to have clear ACE inhibitory activity.
  • the antihypertensive effect of the product according to the invention was studied by giving, since birth, the sour milk product of the invention described in Example 5 to spontaneously hypertensive SHR rats.
  • the controls consisted of three corresponding groups of rats that were given water, milk and commercially available sour milk, respectively.
  • As reference was used a corresponding rat group that was given the Japanese Calpis sour milk product (by Calpis Food Industry Company Ltd.).
  • the blood pressure of all rats was measured at one-week intervals for 13 weeks.
  • the results are presented in Figure 1 as the rise in the systolic pressure as a function of time. It appears clearly from the results that the product according to the invention is capable of preventing considerably elevation of blood pressure both as compared with the control groups and the reference group.
  • Reference example 2
  • the antihypertensive effect of the product of the invention has also been studied on human beings.
  • the test group consisted of 12 randomly selected persons who daily ingested 1.5 dl of the product of the invention described in Example 5 and the control group consisted of 11 randomly selected persons who ingested an equal amount of commercially available fat-free sour milk.
  • Blood pressure was measured at one-week intervals for 8 weeks.
  • the blood pressure of eight persons in the test group was clearly reduced: the systolic pressure for about 13 % on the average and the diastolic pressure for about 12 % on the average, one person was observed to have a minor, less than 5 %, reduction in blood pressure, and three persons were observed to have no changes.
  • the strain Lactobacillus helveticus LBK 16-H was cultivated in MRS broth at a temperature of 37 °C for 24 hours and inoculated in reconstituted milk (10 %) for producing an inoculum. After two cultivation rounds the inoculum (15 %) was inoculated in a fermentor medium which was 9 to 10 % milk made from fat-free milk powder milk and which was sterilized at 100 °C for 10 min. Fermentation was performed at 37 °C for 22 to 24 hours, by mixing strongly all the time. The product can be dried and pulverized or transferred as such to the nanofiltration treatment.
  • the pH of the fermented sour milk obtained in the above-described manner was raised to about 4.6 with KOH and the casein was removed with an inclined screen. Residual casein dust was removed by centrifugal clarifying.
  • GLL Cone lactase (Biocon Ltd., Japan) was added to the whey and it was allowed to hydrolyse at 5 °C for 24 hours for degrading the lactose into mono- saccharides.
  • the whey pretreated in this manner was nanofiltrated through a Nanomax-50 membrane (Millipore). Filtration was performed at 40 °C in a pressure of 30 bar. The whey was filtered to a volumetric concentration ratio of 9.
  • Table 2 The compositions of the obtained concentrate and the dried powder produced therefrom are presented in Table 2.
  • compositions of a concentrate and a dried powder containing antihypertensive peptides Compositions of a concentrate and a dried powder containing antihypertensive peptides
  • the removed casein was neutralized to caseinate and dried.
  • Example 1 The fermentation described in Example 1 was repeated by using (a) fat-containing milk and (b) butter milk in place of the fat-free milk.
  • Example 2(b) The pH of the product of Example 2(b) was raised to about 4.5 and the casein was removed with a curd separator. Lactase was added to the whey and dust was removed with a bactofuge. The whey was then nanofil- trated through an NF membrane (Desal-5, Desal Inc.), evaporated and dried. The composition of the obtained nanofiltration concentrate was very similar to that presented in Table 2.
  • the removed casein comprises large amounts of whey whose antihypertensive peptide content equals to that of fermented sour milk.
  • the casein was used as such in curd cheese, to which antihypertensive peptides were introduced in this manner.
  • the pH of the fermentation broth was raised to 4.6 with KOH, at a temperature of 37 °C, whereby the casein precipitated.
  • the casein was separated with a curd separator and the obtained whey was recovered.
  • the whey contains peptides, lactic acid and salts but no lactose.
  • the major part of the lactic acid and monovalent salts and residual glucose of the whey can be removed by nanofiltration.
  • the nanofiltration retentate can be evaporated to a concentrate or dried to powder, whereby a well concentrated and long presentable preparation containing antihypertensive peptides is obtained.
  • the L. helveticus strains and L. rhamnosus LC705 were cultivated in MRS broth for 24 hours, at 37 °C, from which 1 % inoculum was transferred into milk.
  • Str. thermophilus T101 was cultivated in LM17 broth for 18 h, at 37 °C, wherefrom an inoculum was transferred into milk.
  • the first cultivation was carried out by cultivating all strains separately in milk, incubation at 37 °C for 24 hours.
  • 1 % of the strains in each mixture was pipetted into milk, whereafter co-cultivation was continued for 24 hours, at 37 °C.
  • For the third cultivation 5 to 10 % of the previously obtained co-cultivation was pipetted into milk and incubated at 37 °C for 24 hours.
  • VPP and IPP produced by the L. helveticus LBK-16 H strain and the different microbe mixtures and the concentration of some of the bacteria are presented in Table 3. No mutual differences were observed between the mixtures or the LBK-16 H strain solely, but the other strains did not interfere with proteolysis either.
  • Sour milk containing antihypertensive peptides was prepared by adding 3.5 % of the peptide concentrate obtained as in Example 3 to commercially available sour milk.
  • the composition of the obtained product is presented in Table 4, which also shows the composition of the commercially available sour milk product, AB sour milk, by Valio Oy, for the sake of comparison.
  • Table 4 shows the composition of the commercially available sour milk product, AB sour milk, by Valio Oy, for the sake of comparison.
  • composition of the product according to the invention and that of a commercially available fermented milk product is provided.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un procédé permettant de fabriquer un produit contenant des peptides antihypertenseurs en faisant fermenter une matière première contenant de la caséine avec des bactéries d'acide lactique. L'invention concerne également le produit ainsi obtenu et son utilisation comme produit fonctionnel en tant que tel ou comme ingrédient ou additif de substances comestibles.
EP00972941A 1999-11-01 2000-10-30 Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs Expired - Lifetime EP1226267B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI992360 1999-11-01
FI992360A FI113741B (fi) 1999-11-01 1999-11-01 Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
PCT/FI2000/000942 WO2001032905A1 (fr) 1999-11-01 2000-10-30 Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs

Publications (2)

Publication Number Publication Date
EP1226267A1 true EP1226267A1 (fr) 2002-07-31
EP1226267B1 EP1226267B1 (fr) 2004-05-12

Family

ID=8555541

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00972941A Expired - Lifetime EP1226267B1 (fr) 1999-11-01 2000-10-30 Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs
EP00972940A Expired - Lifetime EP1226230B1 (fr) 1999-11-01 2000-10-30 Lactobacillus helveticus produisant des dipeptides et des tripeptides antihypertenseurs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP00972940A Expired - Lifetime EP1226230B1 (fr) 1999-11-01 2000-10-30 Lactobacillus helveticus produisant des dipeptides et des tripeptides antihypertenseurs

Country Status (23)

Country Link
US (2) US6972282B1 (fr)
EP (2) EP1226267B1 (fr)
JP (2) JP4172681B2 (fr)
KR (2) KR100704441B1 (fr)
CN (2) CN1164761C (fr)
AT (2) ATE266735T1 (fr)
AU (2) AU777795B2 (fr)
CA (2) CA2388354A1 (fr)
CZ (2) CZ302271B6 (fr)
DE (2) DE60010742T2 (fr)
DK (2) DK1226230T3 (fr)
EE (2) EE05461B1 (fr)
ES (2) ES2234686T3 (fr)
FI (1) FI113741B (fr)
HR (2) HRP20020377B1 (fr)
HU (2) HU226200B1 (fr)
NO (2) NO330951B1 (fr)
NZ (2) NZ518470A (fr)
PL (2) PL364790A1 (fr)
PT (2) PT1226267E (fr)
RU (2) RU2270855C2 (fr)
WO (2) WO2001032905A1 (fr)
ZA (2) ZA200203179B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI113741B (fi) * 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
FI112031B (fi) 2002-02-25 2003-10-31 Valio Oy Biologisesti aktiivisen tuotteen uusi käyttö
EP1509609B1 (fr) 2002-06-04 2015-04-22 DSM IP Assets B.V. Hydrolysat de proteines riche en tripeptides
CN100451127C (zh) * 2002-08-09 2009-01-14 科·汉森有限公司 制备具有抗高血压特性的肽的方法
PL378232A1 (pl) * 2003-01-06 2006-03-20 Unilever N.V. Fermentowany produkt mleczny, zawierający tripeptydy VPP i/albo IPP
TWI328457B (en) * 2003-03-18 2010-08-11 Suntory Holdings Ltd Angiotensin-converting enzyme inhibitory peptides
US7718171B2 (en) 2003-04-07 2010-05-18 Chr. Hansen A/S Reducing heart rate in mammals using milk derived fermentation products produced using Lactobacillus helveticus
CA2523410A1 (fr) 2003-05-05 2004-11-18 Unilever Plc Produit a base de caseine hydrolysee comportant des tripeptides ipp et/ou vpp
WO2005096847A1 (fr) * 2004-03-19 2005-10-20 Campina Nederland Holding B.V. Procede de preparation d'un ingredient alimentaire, produit alimentaire possedant des proprietes d'inhibition de l'enzyme de conversion de l'angiotensine i et produits ainsi obtenus
WO2005094848A1 (fr) * 2004-03-31 2005-10-13 Calpis Co., Ltd. Agent visant à empêcher ou supprimer l'hépatopathie et aliment fonctionnel pour empêcher ou supprimer l'hépatopathie
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
JP4723501B2 (ja) * 2004-07-05 2011-07-13 カルピス株式会社 ペプチド混合物の製造法、抗高血圧ペプチド含有発酵乳の製造法及び抗高血圧ペプチド製剤の製造法
CA2569926A1 (fr) * 2004-07-12 2006-01-19 Dsm Ip Assets B.V. Hydrolysats proteiques abaissant la pression sanguine
EP1685764A1 (fr) 2005-01-27 2006-08-02 Globus Egg Sciences B.V. Produits fonctionnels alimentaires hypotenseurs
AU2005279163B2 (en) 2004-09-03 2012-02-02 Chr. Hansen A/S Fermented milk or vegetable proteins comprising receptor ligand and uses thereof
FR2876876B1 (fr) * 2004-10-22 2007-02-16 Gervais Danone Sa Protection d'ingredients alimentaires bioactifs par l'utilisation de microorganismes presentant une capacite de metabolisation reduite
FR2876874B1 (fr) * 2004-10-22 2007-02-16 Gervais Danone Sa Protection d'ingredients alimentaires bioactifs par l'utilisation d'ingredients leurres
JP5106117B2 (ja) * 2004-12-22 2012-12-26 ディーエスエム アイピー アセッツ ビー．ブイ． 単一の酵素工程における血圧降下ペプチド
EP1879465A1 (fr) * 2005-02-09 2008-01-23 Unilever N.V. Composition comprenant un peptide
WO2006089921A1 (fr) * 2005-02-24 2006-08-31 Dsm Ip Assets B.V. Peptides abaissant la pression sanguine du glycomacropeptide
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
BRPI0619381A2 (pt) * 2005-11-28 2011-09-27 Dsm Ip Assets Bv preparações de enzimas que não alteram o paladar
EP1992353B1 (fr) * 2006-02-14 2014-05-07 Calpis Co., Ltd. Vasodilatateur
JP5642346B2 (ja) * 2006-02-14 2014-12-17 カルピス株式会社 動脈硬化予防剤、血管内膜の肥厚抑制剤及び血管内皮の収縮・拡張機能改善剤
EP1820850B1 (fr) * 2006-02-20 2009-02-25 Compagnie Gervais Danone Nouvelles souches de lactobacillus helveticus
ES2384096T3 (es) * 2006-02-20 2012-06-29 Compagnie Gervais Danone Cepas de Lactobacillus helveticus que no fermentan la lactosa
ATE421572T1 (de) * 2006-02-20 2009-02-15 Gervais Danone Sa Neue stämme von lactobacillus helveticus
CN100370019C (zh) * 2006-04-21 2008-02-20 江南大学 一种具有抗高血压作用的植物乳杆菌cw006
RU2457852C2 (ru) * 2006-05-15 2012-08-10 Валио Лтд Новое применение терапевтически эффективных пептидов
EP2040732A4 (fr) 2006-05-15 2009-08-19 Valio Ltd Nouvelle utilisation de peptides thérapeutiquement utiles
KR101492650B1 (ko) * 2006-09-04 2015-02-12 유키지루시 메그밀크 가부시키가이샤 혈중 아디포넥틴 농도 증가 촉진 및/또는 감소 억제제 및 내장 지방 축적 억제제
ES2557160T3 (es) 2006-10-23 2016-01-22 Nestec S.A. Modulación del aroma y el sabor mediante biotransformación en productos lácteos
ES2351230T3 (es) * 2007-02-02 2011-02-01 May, Amadeus Alexander Producto con microorganismos prebióticos vivos.
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
EP2138184B1 (fr) * 2007-03-27 2013-09-18 Calpis Co., Ltd. Tripeptides pour l'utilisation dans le prévention de la maladie glomérulaire du ren
WO2009149880A1 (fr) * 2008-06-12 2009-12-17 Nestec S.A. Souches de lactobacillus helveticus produisant des peptides hypotenseurs
DE102008032828A1 (de) 2008-07-02 2010-01-07 Technische Universität Dresden Tryptophanhaltige Peptide aus alpha-Lactalbumin mit blutdrucksenkender und vasoprotektiver Wirkung für biofunktionelle Lebensmittel
FI122531B (fi) * 2009-09-30 2012-03-15 Valio Oy Juusto ja menetelmä sen valmistamiseksi
RU2453593C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus helveticus, используемый для получения продукции, содержащей лактобактерии
CN102786579B (zh) * 2012-07-17 2014-07-09 上海交通大学 抗高血压活性肽vip
CN102786580A (zh) * 2012-07-17 2012-11-21 上海交通大学 抗高血压活性肽ivp
RU2580052C1 (ru) * 2014-12-24 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" Штамм lactobacillus helveticus вкпм в-11176, полученный на доступных питательных средах
RU2577112C1 (ru) * 2014-12-25 2016-03-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" Штамм lactobacillus helveticus вкпм в-11175, полученный на доступных питательных средах
CA3043392A1 (fr) 2016-12-02 2018-06-07 Fairlife, Llc Poudre de lait sans lactose et sans brunissement, et procedes de fabrication de celle-ci
RU2685912C1 (ru) * 2018-03-14 2019-04-23 Федеральное государственное автономное научное учреждение "Научно-исследовательский институт хлебопекарной промышленности" Штамм бактерий lactobacillus amylolyticus, используемый для приготовления термофильной заквашенной заварки
RU2728171C2 (ru) * 2018-11-08 2020-07-28 Общество с ограниченной ответственностью "Инновационные биотехнологии" (ООО "Инбиотех") Штамм бактерий Lactobacillus helveticus T-5068, используемый в качестве закваски прямого внесения для приготовления кисломолочных продуктов
CN109517763B (zh) * 2018-12-27 2022-03-22 内蒙古农业大学 瑞士乳杆菌h11及其应用
TWI713972B (zh) * 2019-01-14 2020-12-21 大江生醫股份有限公司 改善呼吸道健康之益生菌株及其組合物與用途
WO2021195718A1 (fr) * 2020-04-02 2021-10-07 Ahtesh Fatah Bashir Procédé de fermentation lactique
CN112029784A (zh) * 2020-09-16 2020-12-04 内蒙古农业大学 一个与蛋白水解能力相关的基因及基于该基因的高蛋白水解能力瑞士乳杆菌的筛选方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2483748A1 (fr) * 1980-06-06 1981-12-11 Corning Glass Works Procede d'hydrolyse du lactose contenu dans les lactoserums a l'aide de lactase immobilisee
JPS6153216A (ja) 1984-08-23 1986-03-17 Rikagaku Kenkyusho 高血圧症予防治療剤
JP2782142B2 (ja) * 1992-07-23 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害剤及びその製造法
JP2782153B2 (ja) * 1992-11-09 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害ペプチドの製造法
JP2824821B2 (ja) 1993-11-04 1998-11-18 カルピス株式会社 乳酸菌及び発酵乳製品
GB2294191B (en) 1994-10-06 1997-10-01 Waterford Creamery Ltd Cheese manufacture
JP3782837B2 (ja) * 1995-04-10 2006-06-07 カルピス株式会社 血圧降下剤及びその製造法
JPH09188694A (ja) 1996-01-10 1997-07-22 Otsuka Shokuhin Kk ペプチド、アンジオテンシン変換酵素阻害組成物及びその製法
JP3746556B2 (ja) 1996-02-09 2006-02-15 カルピス株式会社 プラスミド及びプラスミドベクター
US5854029A (en) 1996-08-02 1998-12-29 Calpis Co., Ltd. Method for preparing antihypertensive agent
JP3028411B2 (ja) 1997-09-26 2000-04-04 カルピス株式会社 トリペプチド高生産性ラクトバチルス・ヘルベチカス乳酸菌
JP4727770B2 (ja) * 1997-09-26 2011-07-20 カルピス株式会社 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤
FI104783B (fi) 1998-02-12 2000-04-14 Valio Oy Herasuolajauhe, menetelmä sen valmistamiseksi ja sen käyttö
FI113741B (fi) * 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
US6514941B1 (en) * 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132905A1 *

Also Published As

Publication number Publication date
CN1387577A (zh) 2002-12-25
AU777795B2 (en) 2004-10-28
JP2003513621A (ja) 2003-04-15
EP1226230A1 (fr) 2002-07-31
RU2270855C2 (ru) 2006-02-27
ES2220557T3 (es) 2004-12-16
JP3695648B2 (ja) 2005-09-14
NO20022061D0 (no) 2002-04-30
KR100704441B1 (ko) 2007-04-24
NZ518493A (en) 2003-03-28
ES2234686T3 (es) 2005-07-01
HRP20020378A2 (en) 2003-08-31
PT1226230E (pt) 2005-04-29
CZ294146B6 (cs) 2004-10-13
CN1387564A (zh) 2002-12-25
CZ20021431A3 (cs) 2002-08-14
DE60010742T2 (de) 2005-05-12
FI19992360A (fi) 2001-05-02
CN1164761C (zh) 2004-09-01
AU769432B2 (en) 2004-01-29
HUP0203185A3 (en) 2005-07-28
NO20022062D0 (no) 2002-04-30
EP1226267B1 (fr) 2004-05-12
CA2387738C (fr) 2008-09-16
DK1226230T3 (da) 2005-04-04
FI113741B (fi) 2004-06-15
HRP20020377A2 (en) 2003-08-31
PT1226267E (pt) 2004-08-31
AU1149901A (en) 2001-05-14
CZ20021369A3 (cs) 2002-07-17
HRP20020377B1 (en) 2005-06-30
DE60010742D1 (de) 2004-06-17
KR100718709B1 (ko) 2007-05-16
KR20020060220A (ko) 2002-07-16
HUP0203185A2 (hu) 2003-01-28
JP2003513636A (ja) 2003-04-15
EE05461B1 (et) 2011-08-15
DE60016959D1 (de) 2005-01-27
WO2001032836A1 (fr) 2001-05-10
HU226200B1 (en) 2008-06-30
HRP20020378B1 (en) 2005-06-30
PL355670A1 (en) 2004-05-04
AU1149801A (en) 2001-05-14
PL364790A1 (en) 2004-12-13
NO20022061L (no) 2002-06-28
US6890529B1 (en) 2005-05-10
ZA200203172B (en) 2003-09-23
NZ518470A (en) 2003-03-28
KR20020064895A (ko) 2002-08-10
PL204119B1 (pl) 2009-12-31
NO330951B1 (no) 2011-08-22
WO2001032905A1 (fr) 2001-05-10
ATE285470T1 (de) 2005-01-15
CA2387738A1 (fr) 2001-05-10
HUP0203256A3 (en) 2005-11-28
CZ302271B6 (cs) 2011-01-19
US6972282B1 (en) 2005-12-06
DE60016959T2 (de) 2005-12-22
HUP0203256A2 (hu) 2003-01-28
CN1197956C (zh) 2005-04-20
DK1226267T3 (da) 2004-09-20
ZA200203179B (en) 2003-07-22
EE200200230A (et) 2003-06-16
CA2388354A1 (fr) 2001-05-10
JP4172681B2 (ja) 2008-10-29
NO20022062L (no) 2002-06-28
ATE266735T1 (de) 2004-05-15
EP1226230B1 (fr) 2004-12-22
EE200200231A (xx) 2003-06-16
RU2276689C2 (ru) 2006-05-20

Similar Documents

Publication Publication Date Title
EP1226267B1 (fr) Procede de fabrication d'un produit contenant des tripeptides antihypertenseurs
Leclerc et al. Antihypertensive activity of casein-enriched milk fermented by Lactobacillus helveticus
CN101925674A (zh) 改进的生物活性肽生产
JPH1198978A (ja) トリペプチド高生産性ラクトバチルス・ヘルベチカス乳酸菌
EP1142481B1 (fr) Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum
US20080292750A1 (en) Method of Preparing a Food Ingredient and Food Product Having Angiotensin-I-Converting Enzyme Inhibiting Properties and Products Thus Obtained
MXPA05007267A (es) Producto de leche fermentada que comprende tripeptidos val-pro-pro (vpp) e ile-pro-pro (ipp).
AU2003260281B2 (en) Process for preparing peptides with anti-hypertensive properties
Durak et al. Antihypertensive peptides in dairy products
JPH1033115A (ja) ホエー飲料とその製造法
CN115786189A (zh) 一种高产降压肽的直投式发酵剂及其在制备降压酸奶中的应用
US20050142166A1 (en) Peptides with anti-hypertensive properties
EP1466529A1 (fr) Composition destinée à reduire la fréquence cardiaque
Joshi Value Addition and Sustainable Management of Dairy Industry Byproducts T. Jayasree Joshi, V. Harsha, P. Nandagopal, Asha Ashok, and Sabitra Pokhrel
FI120267B (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidien valmistamiseksi
KR20070009626A (ko) 안지오텐신-ｉ-전환 효소를 억제하는 성질을 갖는 식품원료 및 식품을 제조하는 방법 및 그로부터 수득된 제품
PL241893B1 (pl) Sposób przeprowadzenia selekcji mikroorganizmów proteolitycznych, sposób wytwarzania hydrolizatu białek serwatkowych, zawierającego bioaktywne peptydy i hydrolizat białek serwatkowych

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20020517;LV PAYMENT 20020517;MK;RO;SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040512

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60010742

Country of ref document: DE

Date of ref document: 20040617

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040402055

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20040702

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20041006

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20041007

Year of fee payment: 5

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2220557

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20091022

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20101028

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20101019

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101027

Year of fee payment: 11

Ref country code: GB

Payment date: 20101028

Year of fee payment: 11

Ref country code: GR

Payment date: 20101027

Year of fee payment: 11

LTLA Lt: lapse of european patent or patent extension

Effective date: 20101030

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20111020

Year of fee payment: 12

Ref country code: CH

Payment date: 20111014

Year of fee payment: 12

Ref country code: IE

Payment date: 20111020

Year of fee payment: 12

Ref country code: FR

Payment date: 20111118

Year of fee payment: 12

Ref country code: PT

Payment date: 20111006

Year of fee payment: 12

Ref country code: ES

Payment date: 20111025

Year of fee payment: 12

Ref country code: DK

Payment date: 20111022

Year of fee payment: 12

Ref country code: NL

Payment date: 20111024

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101030

BERE Be: lapsed

Owner name: *VALIO LTD

Effective date: 20121031

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20130430

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130501

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 266735

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121030

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20040402055

Country of ref document: GR

Effective date: 20130508

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20121030

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121030

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130501

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121030

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60010742

Country of ref document: DE

Effective date: 20130501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130430

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130501

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130508

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121030

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20141023

Year of fee payment: 15

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151031